StockData
IMMUTEP Ltd logo

IMMUTEP Ltd (IMMP) company profile

IMMPNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRRUF
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Oct 23, 2026Score 8/30
$3.26−0.14 (-4.12%)

Close on Nov 17, 2026Market cap $24.02MP/E –Yield –

About Immutep

Pharmaceutical Preparations, SIC 2834

Immutep is an enterprise involved in clinical research and development activities. The group contracts with external vendors and specialized research organizations to conduct clinical trials and manufacturing operations. It maintains intellectual property assets, including patents and licensing agreements, while administering share-based incentive programs for its personnel and directors.

The company operates through subsidiaries in France, the United States, Germany, Australia, and the Middle East. Its corporate operations and administrative oversight involve regulatory and accounting functions in Australia, where it engages independent audit services. Specific manufacturing and clinical trial functions are conducted across these international jurisdictions.

Summary of the business section of Immutep's latest annual report, written by StockData.

Company profile

Company

Legal name
IMMUTEP Ltd
Headquarters
Sydney,, C3
Address
Level 32, Suite 32.07 Australia Square, 264 George Street NSW 2000
Phone
612 8315 7003
Employees
46, Jun 30, 2026
Industry
Pharmaceutical Preparations
Incorporated in
C3
Fiscal year ends
June 30
Auditor
PricewaterhouseCoopers, Sydney, Australia

Stock & identifiers

Ticker
IMMP
Other tickers
PRRUF
Exchange
Nasdaq
IPO date
Apr 19, 2012
Shares outstanding
1.47B, Jun 30, 2026
Filer category
Accelerated filer
Stock splits
1-for-20 reverse, Sep 28, 2026; 1-for-9.5 reverse, Sep 25, 2020; 1-for-3.33 reverse, Dec 28, 2016
SEC CIK
1506184
FIGI
BBG002WD6SY6
Share class FIGI
BBG002WD6TP4
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Marc VoigtSee Remarks, Director85,700
Deanne Diem MillerChief Operating Officer2,867,305
Christian MuellerChief Development Officer3,774,048
Stephan Karel Gerard WinckelsChief Medical Officer92,935
Elisabeth Amanda BoyceDirector423,288
Pete A. MeyersDirector4,052,173
Frederic Joseph Daniel TriebelDirector170,610
Russell J. HowardDirector1,717,977

Employees

Headcount reported in annual reports

“As of June 30, 2026, we employed 46 people.”

Corporate history

Events identified from SEC filings

DateEventDetails
Dec 1, 2017Name changeName changed from Prima BioMed Ltd to IMMUTEP Ltd

See a number that looks wrong?